Arteaga named to Komen scientific advisory boardAug. 2, 2012, 10:27 AM
Carlos Arteaga, M.D., associate director for Clinical Research and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named to the Scientific Advisory Board of the Susan G. Komen for the Cure Breast Cancer Research Foundation.
Komen is the one of the largest nonprofit organizations dedicated to funding breast cancer research and providing support for patients, survivors and their families.
Since its inception in 1982, Susan G. Komen for the Cure has invested more than $1.9 billion in breast cancer research, education and support programs.
The Komen Scientific Advisory Board is a six-member group of cancer investigators and advocates who work to enhance the organization’s scientific peer review process and support other Komen activities.
Arteaga was named to the advisory board because of his “experience, leadership, knowledge and drive for innovation in breast cancer research.” Board members, who serve a three-year term, provide insight and advice about the best research directions to fund and assist with medical information for breast cancer education.
“I am honored by the invitation to join this important advisory group,” said Arteaga. “Komen has been a great partner and supporter of our breast cancer research here at VICC and I am pleased to assist with their research and education mission.”
Arteaga previously served for two years as a member of the Komen Scholars, a group of international investigators with a wide range of expertise, including clinical and laboratory research, pathology, radiation oncology, surgery, pathology, prevention and other research disciplines and specialties.
Arteaga holds the Donna S. Hall Chair in Breast Cancer. His research has been instrumental in characterizing the role of several key pathways in breast cancer, including those responsible for cell growth, division and metastasis.